Page 5«..4567..1020..»

Category Archives: Muscular Dystrophy Treatment

Bayer: Transforming Healthcare through Collaborations and Breakthrough Innovation – Taiwan Business TOPICS – Taiwan Business TOPICS

Posted: Published on February 2nd, 2021

Finding effective solutions to the worlds health issues requires novel, holistic approaches and collaborative ingenuity. Healthcare companies must therefore increasingly shift their focus to the research and development of medical technologies, biopharmaceuticals, and innovative therapies to treat conditions and diseases that are difficult or nearly impossible to tackle using traditional medicines. Such a reality is well understood by Bayer AG Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Bayer: Transforming Healthcare through Collaborations and Breakthrough Innovation – Taiwan Business TOPICS – Taiwan Business TOPICS

Orchard Therapeutics Appoints Braden Parker as Chief Commercial OfficerCommercial Launch of Libmeldy in Europe On-Track for 1H 2021 – BioSpace

Posted: Published on February 2nd, 2021

BOSTONandLONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) --Orchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Orchard Therapeutics Appoints Braden Parker as Chief Commercial OfficerCommercial Launch of Libmeldy in Europe On-Track for 1H 2021 – BioSpace

Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology – PRNewswire

Posted: Published on January 24th, 2021

HACKENSACK, N.J., Jan. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology – PRNewswire

Muscular Dystrophy Treatment Market Trends, Drivers, Strategies, Applications and Competitive Landscape Till 2026 | Santhera Pharmaceuticals, PTC…

Posted: Published on January 24th, 2021

The Global Muscular Dystrophy Treatment Market report provides a holistic evaluation of the market for the forecast period (20192025). The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market. These factors; the market dynamics involve the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Muscular Dystrophy Treatment Market Trends, Drivers, Strategies, Applications and Competitive Landscape Till 2026 | Santhera Pharmaceuticals, PTC…

Dr. Artero’s Lab Researching on microRNA-based treatments for Myotonic Dystrophy Type 1 by Translational Genomics Group – PRNewswire

Posted: Published on January 24th, 2021

About Myotonic Dystrophy Type 1 Myotonic dystrophy type 1 (DM1) is a life-threatening and chronically debilitating disease. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Dr. Artero’s Lab Researching on microRNA-based treatments for Myotonic Dystrophy Type 1 by Translational Genomics Group – PRNewswire

HC asks medical team to submit report on siblings with muscular dystrophy – The Hindu

Posted: Published on January 24th, 2021

The Delhi High Court on Monday directed the city government to constitute a medical team to check on a sister and brother siblings suffering from muscular dystrophy within five days. Justice Pratibha M. Singh asked the medical team to submit a report on the conditions of the siblings before the next date of hearing on January 28 Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on HC asks medical team to submit report on siblings with muscular dystrophy – The Hindu

Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose) – PRNewswire

Posted: Published on January 24th, 2021

NEW YORK, Jan. 22, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the Japanese Patent Office (Japanese patent number 2016-512480) covering SLS-005 titled: "Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose". Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose) – PRNewswire

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes – GlobeNewswire

Posted: Published on January 24th, 2021

January 19, 2021 09:15 ET | Source: Capricor Therapeutics -Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- -Publication Further Supports Capricors Exosome Platform Advancement- LOS ANGELES, Jan. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes – GlobeNewswire

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares -…

Posted: Published on January 24th, 2021

CAMBRIDGE,Mass., Jan. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares -…

FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 -…

Posted: Published on December 28th, 2020

December 22, 2020 07:00 ET | Source: FibroGen, Inc SAN FRANCISCO, Dec. Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2 -…

Page 5«..4567..1020..»